In recent years, the use of chimeric antigen receptor T-cell (CAR-T) therapy which targets CD19 antigen present on the surface of B-cells, has gained significant attention as a treatment option against aggressive and refractory forms of B-ALL. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.